BioSpace

Newron reveals 5 deaths in late-stage schizophrenia program as FDA maintains hold

After one patient death prompted an FDA hold this spring, Newron Pharmaceuticals has now shared that a total of four fatalities have been recorded among participants receiving its schizophrenia candidate. A fifth death was recorded among those taking the placebo.

By BioSpace

1 min read
Newron reveals 5 deaths in late-stage schizophrenia program as FDA maintains hold
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights